CAB-LA is an intramuscular injectable, long-acting form of PrEP, with the first 2 injections administered 4 weeks apart, followed thereafter by an injection every 8 weeks.
CAB-LA was shown to be safe and highly effective among cisgender women, cisgender men who have sex with men, and transgender women who have sex with men in 2 randomized controlled trials, HPTN 083 and HPTN 084.
Together, these landmark studies found that use of CAB-LA resulted in a 79% relative reduction in HIV risk compared with oral PrEP, where adherence to taking daily oral medication was often a challenge.
13384
在检查社区对暴露前预防措施偏好的研究中还发现，长效注射剂可被人接受，且有时被列为首选。
Long-acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences.
13385
今天的2022年艾滋病大会新闻发布会也标志着旨在加快全球获得长效注射用卡博特韦的新联盟的启动。
Today’s press conference also marks the launch of a new coalition to accelerate global access to CAB-LA.
Convened by WHO, Unitaid, UNAIDS and The Global Fund, the coalition will identify market interventions needed to advance near- and long-term access to CAB-LA, establish financing and procurement for the drug, provide implementation support to global HIV prevention programs and issue policy guidance, among other activities.
“To achieve UN prevention goals, we must push for rapid, equitable access to all effective prevention tools, including long-acting PrEP,” said Rachel Baggaley, Lead of the Testing, Prevention and Populations Team at Global HIV, Hepatitis and STI Programmes at WHO.
13388
这意味着要克服低收入和中等收入国家的关键障碍，包括实施挑战和成本。”
“That means overcoming critical barriers in low- and middle-income countries, including implementation challenges and costs.”
13389
世卫组织将继续支持循证战略以增加暴露前预防措施的获取和吸收，包括对长效注射用卡博特韦的采用。
WHO will continue to support evidence-based strategies to increase PrEP access and uptake, including through the adoption of CAB-LA.